Price to earnings forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article provides financial information for SIGA Technologies Inc. (NASDAQ: SIGA), specifically focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering tools and data for market analysis. The content is primarily a listing of navigation options and disclaimers for the TradingView website.
Enterprise value to EBITDA forward of SIGA Technologies Inc. – NASDAQ:SIGA
This page from TradingView displays the Enterprise Value to forward EBITDA for SIGA Technologies Inc. (NASDAQ: SIGA). It indicates that the market was closed with no trades. The content is primarily a financial data point for the company, accessible through TradingView's platform.
Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Raising a New Value-Defensive Story?
SIGA Technologies (SIGA) was reclassified in June 2026, moving from Russell growth benchmarks to the Russell 2000 Defensive and Value-Defensive indices. This shift, alongside a US$28.08 million ESOP-related shelf registration, redefines the company's investment narrative from a pure growth play to a more defensive, cash-generative stock. While core catalysts remain unchanged, the reclassification highlights existing risks concerning earnings volatility and capital allocation.
Price to sales forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article focuses on the "Price to sales forward" metric for SIGA Technologies Inc. (NASDAQ: SIGA). It provides a high-level overview of this financial ratio for the company, accessible through TradingView. The content appears to be a financial data point without deeper analysis or commentary.
Enterprise value to revenue forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article focuses on the enterprise value to revenue forward metric for SIGA Technologies Inc. (NASDAQ: SIGA). It provides a high-level overview of the company's financial data within the context of the pharmaceutical and health technology sectors. The content is primarily a listing of navigation and copyright information from the TradingView platform.
SIGA Technologies, Inc.(NasdaqGM: SIGA) dropped from Russell 2500 Growth Benchmark
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been removed from the Russell 2500 Growth Benchmark, according to an S&P Capital IQ report published on June 29, 2026. This news follows several other index changes for the company, including being dropped from the Russell Small Cap Comp Growth Benchmark and Russell 2000 Growth Benchmark, while also being added to the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious disease treatments, with its flagship product TPOXX approved for smallpox and other related viruses.
SIGA Technologies, Inc.(NasdaqGM: SIGA) dropped from Russell 2000 Growth Benchmark
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been removed from the Russell 2000 Growth Benchmark and the Russell 3000E Growth Benchmark. This news follows a previous report that the company was added to the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious diseases, with its primary product, TPOXX, an antiviral medicine for smallpox, monkeypox, and cowpox.
SIGA Technologies, Inc.(NasdaqGM: SIGA) added to Russell 2000 Value-Defensive Index
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been included in the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious disease treatments, with its flagship product TPOXX being an antiviral medicine for smallpox and monkeypox. The article also provides recent news on SIGA, including its earnings reports and dividend declarations.
SIGA Technologies Inc Actuals & Estimates (NASDAQ:SIGA)
This article provides an overview of SIGA Technologies Inc. (NASDAQ:SIGA) stock performance, financial data, and analyst estimates. It highlights recent stock price changes, future forecasts, historical highs and lows, and key financial metrics like net income and EBITDA. The content also includes information on the company's next earnings date and technical analysis signals.
SIGA Technologies Inc (SIGA) Financial Health: Profitability & Balance Sheet Analysis
SIGA Technologies Inc (SIGA) has a current financial score of 9.00, ranking 21st out of 157 in the Pharmaceuticals industry, indicating robust financial health and high operating efficiency. Despite this strong overall score, the company reported a year-over-year revenue decrease of 11.34% to $6.24 million and a significant net profit decrease of 746.17% in its latest quarter. The analysis highlights key financial metrics like cash and cash equivalents, total assets, and free cash flow as aspects where relevant data has not yet been disclosed by the company.
SIGA Technologies Inc (SIGA) Valuation: PE, PB & Fair Value Analysis
SIGA Technologies Inc (SIGA) currently holds a valuation score of 7.37, ranking 129th out of 157 companies in the Pharmaceuticals industry. Its P/E ratio stands at 15.27, which is a considerable increase from its recent low but still below its recent high. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
SIGA Technologies Inc (SIGA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of SIGA Technologies Inc (SIGA), listing its major individual and institutional holders and their respective proportional ownership. It also provides a breakdown of shareholder types and a historical overview of institutional shareholding changes over several quarters.
SIGA Technologies Inc (SIGA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of SIGA Technologies Inc. (SIGA), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock is currently trading between a resistance of $4.67 and a support of $4.07, suggesting a range-bound swing trading opportunity. Technical indicators like MACD and TRIX show sell signals, while most moving averages also indicate a sell signal, with a current price momentum score of 6.66.
SIGA Technologies Inc (SIGA) Institutional Confidence
The article analyzes the institutional confidence in SIGA Technologies Inc (SIGA), noting its current shareholding score of 5.00, ranking 73rd in the Pharmaceuticals industry. Institutional shareholding proportion increased by 10.57% quarter-over-quarter, with Hotchkis & Wiley being the largest institutional shareholder. The article also lists major institutional shareholders and their recent activity.
SIGA SEC Filings - Siga Technologie 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Siga Technologie (SIGA) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent notable filings include a Form 4 detailing CEO Diem Nguyen's equity compensation activity in January 2026, and Q3 2025 results showing lower quarterly revenue but strong nine-month profit. The filings document the company's business focused on TPOXX and infectious-disease countermeasures, with updates on revenue, product deliveries, and R&D.
SIGA Technologies (SIGA) director exercises RSUs and disposes shares to issuer
SIGA Technologies director Harold Eugene Ford Jr. engaged in several equity transactions on June 9, 2026. He disposed of 7,235 common stock shares to the issuer at $4.39 each and exercised derivative awards to acquire 24,116 common stock shares at $0.00. Additionally, he received a new grant of 34,169 restricted stock units (RSUs) which will vest at the company's 2027 annual meeting, with a portion potentially settled in cash.
SIGA Technologies (SIGA) director exercises RSUs and returns 7,235 shares
SIGA Technologies director John M. Keane reported exercising 24,116 restricted stock units (RSUs) into common stock and returning 7,235 shares to the company at $4.39 per share. He also received a new grant of 34,169 RSUs, which will fully vest at the company's 2027 annual meeting. These transactions are considered routine director equity compensation and have a neutral impact on shareholders.
SIGA Technologies (SIGA) director reshapes holdings with RSU exercise
SIGA Technologies director Gary J. Nabel has adjusted his holdings through RSU transactions. He exercised 24,116 restricted stock units and then disposed of 7,235 common shares back to the company for $4.39 per share, leaving him with 80,989 direct shares. Additionally, Nabel received a new grant of 34,169 RSUs that will vest in 2027, with a portion potentially being cash-settled for tax purposes.
SIGA Technologies (SIGA) director adjusts stock and RSU stake
SIGA Technologies director Julian Nemirovsky reported equity compensation changes, including the exercise of 24,116 restricted stock units (RSUs) into common shares and the disposition of 7,235 common shares back to the company at $4.39 per share. He also received a new grant of 34,169 RSUs vesting in 2027. Following these transactions, Nemirovsky directly holds 80,989 common shares and 34,169 RSUs.
SIGA Technologies (SIGA) director logs RSU grant, exercise and share return
SIGA Technologies director Holly L. Phillips reported multiple equity compensation transactions. These included the disposition of 7,235 common shares back to the company, the exercise of derivative securities to acquire 24,116 common shares, and the grant of 34,169 restricted stock units (RSUs). The RSUs represent contingent rights to receive common stock on a one-for-one basis, with some potentially settling in cash to address tax obligations.
SIGA Technologies (SIGA) director reports RSU exercise, share disposition and new RSU grant
SIGA Technologies director Joseph W. Marshall III reported recent equity compensation activities, including the exercise of 24,116 restricted stock units (RSUs) and the disposition of 7,235 common shares back to the issuer. Following these transactions, he holds 246,523 shares. Marshall also received a new grant of 34,169 RSUs that are set to vest on the date of the company's 2027 annual meeting, with a portion potentially settled in cash.
SIGA Technologies held 2026 annual meeting; director/officer changes disclosed
SIGA Technologies held its 2026 annual annual meeting of stockholders on June 9, 2026. The company disclosed changes to its directors or certain officers under Item 5.02, effective on the meeting date. The specifics of the departures and/or appointments were not disclosed in this summary.
[8-K] SIGA TECHNOLOGIES INC Reports Material Event
SIGA Technologies Inc. held its 2026 annual meeting where stockholders approved an amendment to the 2010 Stock Incentive Plan, increasing authorized shares by 6,500,000 to a total of 15,000,000. In addition, shareholders elected eight directors, ratified PricewaterhouseCoopers LLP as the independent accounting firm, and approved executive officer compensation. The company filed an 8-K report detailing these events, including the full voting results.
SIGA Technologies (SIGA) AGM 2026 Summary
This article summarizes SIGA Technologies' (SIGA) 2026 Annual General Meeting (AGM), detailing financial performance, including $95 million in total revenues for 2025 and $43 million returned to shareholders. It also highlights strategic initiatives such as advancing TPOXX pediatric formulation and engaging with the U.S. government for new procurement contracts. The meeting confirmed quorum and discussed future plans.
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
SIGA Technologies, Inc. has announced an agreement to sell its antiviral drug TPOXX (tecovirimat) to member states of the Association of Southeast Asian Nations (ASEAN). This agreement, coordinated with Meridian Medical Technologies, LLC and signed by Brunei Darussalam's Ministry of Health on behalf of ASEAN, aims to strengthen the region's preparedness for potential public health events and expand TPOXX's global access. The deal signifies a strategic step for SIGA into the highly populated Asian market to enhance orthopoxvirus preparedness, though financial terms were not disclosed.
SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed
SIGA Technologies experienced a 9.9% stock drop following a significant Q1 2026 revenue miss and a sharper net loss. The company reported revenue of US$6.24 million, down from US$7.04 million, and a net loss of US$3.45 million, compared to US$0.41 million the previous year. This performance highlights SIGA's vulnerability to inconsistent government contract timing and its impact on profitability and share price, despite management's readiness to return cash via special dividends.
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings
Despite seemingly soft headline earnings, SIGA Technologies' shareholders may have reason for optimism due to positive underlying factors. The company's accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting its earnings potential might be understated. While earnings per share fell, the strong conversion of profit to free cash flow is a positive indicator for the company.
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings
Despite what appears to be lackluster earnings, SIGA Technologies, Inc.'s shareholders might have reasons to be optimistic. The company's strong accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting that reported profits may actually understate its true earnings potential. This strong cash conversion ability could be a positive underlying factor balancing the softer headline numbers.
SIGA Technologies Q1 2026 Earnings: Minimal Deliveries, $13M TPOXX Order Expected in Q2 - News and Statistics
SIGA Technologies reported minimal product deliveries for Q1 2026 but anticipates a $13 million oral TPOXX order from an international customer and additional IV TPOXX deliveries to the Strategic National Stockpile (SNS) in Q2. CEO Diem Nguyen highlighted the company's commitment to global biological threat preparedness, emphasizing TPOXX's suitability for large-scale deployment. The company remains engaged with the U.S. government and expresses confidence in its long-term outlook despite quarterly variability.
Siga Technologies Q1 Earnings Call Highlights
Siga Technologies reported a first-quarter loss due to minimal product deliveries but anticipates an increase in Q2 from an international order and U.S. Strategic National Stockpile deliveries. CEO Diem Nguyen emphasized the company's focus on partnering with governments to address biological threats, particularly smallpox, with TPOXX. The company continues contract discussions with the U.S. government and is expanding international efforts, including a new agreement with Hikma for the Middle East and North Africa region.
SIGA: Q1 2026 revenue declined and net loss widened, but large TPOXX deliveries and global expansion are underway
SIGA Technologies Inc. experienced lower revenues and a wider net loss in Q1 2026 compared to the previous year. Despite this, the company anticipates major TPOXX deliveries in Q2 and Q3 and has expanded internationally through a special dividend payment and an exclusive MENA license agreement. This news was based on an SEC 8-K Current Report filed on May 7, 2026.
$39M in TPOXX shipments ahead as SIGA posts quarterly loss
SIGA Technologies (SIGA) reported a total revenue of $6.2 million and a net loss of $3.5 million for the first quarter of 2026, with product sales falling to $3.5 million from $5.8 million in the prior year. Despite the quarterly loss, the company anticipates delivering approximately $13 million of oral TPOXX in Q2 2026 to an international customer and $26 million of IV TPOXX to the U.S. Strategic National Stockpile by the end of Q3 2026. SIGA also announced an exclusive license agreement with Hikma for the MENA region and paid a special cash dividend of $0.60 per share in April 2026.
SIGA Technologies (NASDAQ: SIGA) Q1 loss, dividend and mpox label change
SIGA Technologies reported a challenging Q1 2026 with a net loss of $3.5 million due to declining revenue and rising costs, contrasting with a smaller loss and higher revenue in the prior year primarily due to the absence of international TPOXX® sales. Despite the financial dip, the company maintained a strong cash position of $145.6 million even after paying a special cash dividend of $0.60 per share. Regulatory news included the EMA recommending against Tecovirimat-SIGA's use for mpox, though its approval for smallpox and other orthopox indications remains, and the BARDA contract continues to present significant future revenue potential.
SIGA (NASDAQ: SIGA) Q1 2026 revenue falls as net loss widens
SIGA Technologies reported a net loss of $3.5 million for Q1 2026, widening from $0.4 million in the prior-year quarter, as total revenues decreased to $6.2 million from $7.0 million. The decline was primarily driven by lower product sales and supportive services, coupled with higher operating expenses. The company also declared a special cash dividend of $0.60 per share, which significantly impacted current liabilities and stockholders' equity.
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA Technologies, Inc. reported financial results for the three months ended March 31, 2026, including a net loss of $3.5 million. The company is on track to deliver $13 million of oral TPOXX to an international customer and $26 million of IV TPOXX to the U.S. Strategic National Stockpile over the second and third quarters of 2026. Additionally, SIGA announced an exclusive license agreement with Hikma MENA FZE for commercialization of oral TPOXX in the MENA region and declared a special cash dividend of $0.60 per share.
SIGA Technologies, Inc. Q1 2026 Earnings Call Summary
SIGA Technologies, Inc. discussed its Q1 2026 earnings, highlighting varied performance due to government procurement cycles but emphasizing long-term value from smallpox preparedness. The company outlined strategic initiatives including focusing on underrepresented regions, advancing its pediatric program, and targeting an FDA submission for Post-Exposure Prophylaxis (PEP). SIGA also addressed regulatory developments, such as the reaffirmation of TPOXX for core smallpox indications despite the withdrawal of the MPOXX indication, and continued special dividends despite revenue fluctuations.
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA Technologies, Inc. reported financial results for the three months ended March 31, 2026, including product sales of $3.5 million and a net loss of $3.5 million. The company expects to deliver over $35 million of TPOXX to the U.S. Government and an international customer in Q2 and Q3 2026, and announced an exclusive license agreement with Hikma MENA FZE for oral TPOXX in the MENA region. SIGA also declared a special cash dividend of $0.60 per share paid in April 2026.
SIGA CEO, CFO to discuss Q1 results and business update May 7
SIGA Technologies, Inc. (Nasdaq: SIGA) announced that its CEO Diem Nguyen and CFO Daniel Luckshire will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 P.M. ET to provide a business update and discuss first-quarter 2026 financial results. The call will be accessible via live webcast on the company's website and through dial-in numbers, with a replay available for two weeks. Historically, similar announcements have been followed by mixed share reactions, averaging a -2.81% move.
Investors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high call option trading volume, with investors purchasing 1,200 call options, a 1,438% increase from the typical daily volume. This surge in options activity comes as several institutional investors have recently adjusted their holdings in the specialty pharmaceutical company. Siga Technologies' stock is currently trading down, with recent financial results reporting a loss per share and the company having declared a special dividend.
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
SIGA Technologies, Inc. announced that its management will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 P.M. ET to provide a business update following the release of their first-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A live webcast and replay will be available on the company's website.
SIGA TECHNOLOGIES INC SEC Filing
This article reports on a recent ARS SEC filing by SIGA Technologies Inc. (SIGA) on April 28, 2026. The filing has a low impact and neutral sentiment, and the full document is available as a PDF. The article also provides an overview of SIGA's stock data, rankings, latest news, and other recent SEC filings.
SIGA Technologies (SIGA) details 2026 virtual meeting, pay and plan votes
SIGA Technologies' 2026 Annual Meeting will be held virtually on June 9, 2026, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the 2010 Stock Incentive Plan. In 2025, CEO Diem Nguyen's total compensation was $3,244,492, comprising salary, cash bonus, and stock awards, reflecting the company's pay-for-performance philosophy that ties executive compensation to corporate and individual performance. The company proposes adding 6.5 million shares to the incentive plan to attract and retain talent and align executive interests with stockholder value creation.
SIGA Technologies declares $0.60/share
SIGA Technologies has declared a cash dividend of $0.60 per share.
SIGA PE Ratio & Valuation, Is SIGA Overvalued
SIGA Technologies Inc. (SIGA) is considered overvalued, with its current forward P/E ratio of 57.47 significantly exceeding its five-year average of 8.92. The fair price for SIGA is estimated to be between $0.90 and $1.63, starkly contrasting its current price of $5.24, indicating it is overvalued by 220.92%. The company's P/S ratio of 1.74, despite being lower than the competitor average, is deemed unsustainable given its robust revenue decline of -95.34%.
The Technical Signals Behind (SIGA) That Institutions Follow
This article provides a technical analysis of Siga Technologies Inc. (NASDAQ: SIGA) for institutional followers. It outlines key findings, AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging), and a multi-timeframe signal analysis indicating near-term strong sentiment but neutral mid and long-term outlooks, with elevated downside risk.
Q3 2025 SIGA Technologies Inc Earnings Call Transcript
SIGA Technologies Inc. (SIGA) reported strong financial results for the first nine months of 2025, with $86 million in product revenue and a robust cash position of $172 million. Despite a net loss in Q3 2025, the company is actively engaged with the US government for future antiviral treatments and advancing its pipeline, including pediatric and post-exposure prophylaxis programs. Shareholder value commitment is evident through $230 million returned since 2020 via dividends and share buybacks, though concerns include questions from the EMA regarding product efficacy and potential delays due to the US government shutdown.
Siga Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high options trading volume on Wednesday, with traders acquiring 1,200 call options, a 1,438% increase over average. This activity follows the company's declaration of a special dividend of $0.60 per share, payable on April 23rd to stockholders of record on April 7th. The specialty pharmaceutical company, known for its smallpox antiviral TPOXX, is currently rated "Hold" by analysts, and its stock is trading around $5.17 with a market capitalization of approximately $370.4 million.
SIGA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for SIGA Technologies Inc. (SIGA), rating it a "Strong Sell" based on various technical indicators. It details moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels for the stock. The analysis highlights that SIGA is trading below its significant moving averages, suggesting a bearish long-term trend.
SIGA SEC Filings - Siga Technologie 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Siga Technologie (SIGA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details SIGA's financial condition, business activities, and material events, with AI-powered summaries to highlight key information from lengthy documents. The article mentions recent filings like the Q3 2025 earnings press release and insider trading activities.
Does SIGA (SIGA)’s Repeat Special Dividend Reveal a Deeper Shift in Its Capital Allocation Priorities?
SIGA Technologies Inc. recently declared a special cash dividend of US$0.60 per share, payable on April 23, 2026, crediting its strong balance sheet and ongoing work on smallpox preparedness. This repeat dividend underscores management's confidence in cash reserves and their ability to return capital even during slower sales periods, despite the inherent risks associated with unpredictable government contract visibility. Investors are encouraged to consider the company's reliance on a limited number of government buyers and various fair value estimates when evaluating the stock.
